Paris, France, April 25, 2024 “ eyeDNA Therapeutics (˜eyeDNA™), a newly created subsidiary of Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies,...
Paris, France, March 27, 2024 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following...
Coave Receives Grant from the ALS Association to Advance its CTx-TFEB Program
Paris, France, October 12th, 2023“ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies, announces the formation of its new Scientific Advisory Board...
Paris, France, September 28, 2023 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
Paris, France, September 21, 2023 “ Coave Therapeutics (˜Coave™), a genetic medicine company focused on developing life-changing therapies for CNS (Central Nervous System) and eye diseases, announces...
CTx-PDE6b demonstrated clinically meaningful benefit in visual functions at the highest dose and exhibits a good safety profile Positive results from the study to date support preparations for a...
Paris, France, May 17, 2023 - Coave Therapeutics (‘Coave’), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, today announces that it will participate at the following conferences:
New data to be presented at ASGCT 2023 Paris, France, May 4, 2023 - Coave Therapeutics (˜Coave™), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS...
Coave Therapeutics to Present at Upcoming Conferences